tirzepatide research (GLP-1/GIP) - 15mg Tirzepatide - Injectable Peptide
Description
2 Materials and methods This study was designed and conducted according to the registration requirements of the PROSPERO database (CRD42024592308) and aims to systematically evaluate the gastrointestinal adverse effects of different GLP-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes mellitus (T2DM)
Uses: Type 2 diabetes, weight management
Ask: Does my plan cover [drug name] for [diagnosis code]
Li J, Xie J, Han Y, Zhang W, Wang Y, Jiang Z
10.1016/j.jstrokecerebrovasdis.2017.12.015 111
The FTI was slightly elevated at 10.9
